These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 24566807

  • 21. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
    Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.
    Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
    [Abstract] [Full Text] [Related]

  • 25. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 26. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM, Johnson BH, Wenten M, Watson C.
    Clin Ther; 2013 Oct 30; 35(10):1501-12. PubMed ID: 24139422
    [Abstract] [Full Text] [Related]

  • 27. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A, Patanella AK, Nociti V, Marti A, Frisullo G, Plantone D, De Fino C, Fetta A, Batocchi AP, Rossini PM, Mirabella M.
    Eur Neurol; 2015 Oct 30; 73(1-2):57-65. PubMed ID: 25402749
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Giovannoni G, Naismith RT.
    Neurology; 2014 Apr 08; 82(14):1196-7. PubMed ID: 24610331
    [Abstract] [Full Text] [Related]

  • 30. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
    Jander S, Turowski B, Kieseier BC, Hartung HP.
    Mult Scler; 2012 Nov 08; 18(11):1650-2. PubMed ID: 23100527
    [Abstract] [Full Text] [Related]

  • 31. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May 08; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 32. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.
    Mult Scler; 2017 Feb 08; 23(2):234-241. PubMed ID: 27055806
    [Abstract] [Full Text] [Related]

  • 33. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.
    JAMA Neurol; 2015 Jan 08; 72(1):31-9. PubMed ID: 25419615
    [Abstract] [Full Text] [Related]

  • 34. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 08; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 35. Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
    Braune S, Lang M, Bergmann A, NTC Study Group.
    J Neurol; 2013 Dec 08; 260(12):2981-5. PubMed ID: 24008757
    [Abstract] [Full Text] [Related]

  • 36. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
    Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A, OFSEP Investigators.
    JAMA Neurol; 2024 May 01; 81(5):490-498. PubMed ID: 38526462
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D, Gilden D.
    Neurology; 2012 Nov 06; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract] [Full Text] [Related]

  • 39. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N, Tambour M, Henriksson F, Fredrikson S.
    J Med Econ; 2013 Nov 06; 16(3):349-57. PubMed ID: 23211038
    [Abstract] [Full Text] [Related]

  • 40. Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients.
    Ribeiro de Barros AH, Fiadeiro Sequeira JP, Lopes de Sousa AS, Cheganças Capela CM, Gomes Pedrosa RM, Dos Santos Manita MA.
    Clin Neuropharmacol; 2018 Nov 06; 41(4):129-135. PubMed ID: 29927805
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.